Severe COVID-19 infection in patients with cancer is characterized by a distinct pattern of immunologic dysfunction, notably muted adaptive immune responses compared with non‑cancer patients. Using integrated proteomic and metabolomic profiling of matched cohorts of cancer and non‑cancer patients with or without COVID‑19, the investigators identified dysfunctional cysteine metabolism as uniquely associated with severe COVID‑19 in the cancer population. The authors report that this redox‑linked metabolic perturbation corresponds with markers of impaired adaptive immunity in the affected patients.
To test whether cysteine supplementation could reverse immune dysfunction, the team conducted a single‑institution phase II prospective clinical trial (ClinicalTrials.gov NCT04374461) of N‑acetylcysteine (N‑AC) in hospitalized patients with severe, steroid‑refractory COVID‑19. The trial included two arms: Arm A enrolled mechanically ventilated patients or those admitted to an intensive care unit; Arm B enrolled patients requiring at least 2 L supplemental oxygen by nasal cannula but not admitted to the ICU. General inclusion criteria required documented COVID‑19 and age ≥18 years; for Arm A an absolute lymphocyte count (ALC) >1 cell/µL was required except for patients with lymphoid malignancy, who could enroll regardless of ALC. There were no other strict inclusion or exclusion criteria reported. The protocol was approved by the institution’s internal review board.
Concomitant anti‑COVID therapies were permitted at any time point during the trial, including steroids, antiviral agents, monoclonal antibodies, convalescent plasma, and tocilizumab. The authors note that this was a single‑institution study and that sequencing data will be made available on dbGaP at the time of publication; clinical data can be requested from the corresponding author.
Investigators report that treatment of cancer patients with steroid‑refractory severe COVID‑19 with N‑AC improved clinical outcomes compared with disease severity–matched hospitalized patients treated during the period immediately preceding initiation of the clinical trial. The source describes this comparison but does not provide detailed numerical outcome measures in the abstract; specific outcome metrics and statistical results were not reported in the provided text.
N‑AC treatment was associated with reductions in circulating markers of innate inflammation. The authors further observed a decrease in the population of severe disease–associated MHC‑II low monocytes after N‑AC therapy. These changes are presented as part of the immunologic effects accompanying N‑AC administration in the treated cancer patients.
Following N‑AC treatment, circulating CD8+ T cell abundance increased, along with markers of activation and effector differentiation. The authors link these changes to restoration of adaptive immune competence in patients whose immune responses had been muted during severe COVID‑19.
Mechanistic studies reported in the source indicate that N‑AC reduced prostaglandin E2 (PGE2)‑driven interactions between suppressive monocytes and T cells. The PGE2‑mediated monocyte–T cell interactions were shown to be sufficient to limit T cell expansion and effector differentiation in a manner dependent on signal dose and T cell avidity. In addition, N‑AC lowered the activity of inhibitory, redox‑sensitive transcription factors such as KLF6, a change the authors associate with enabling clonal expansion and effector T cell differentiation. These mechanistic observations were derived from analyses reported alongside the clinical trial findings.
To validate the human observations, the investigators tested N‑AC in two murine models of severe respiratory viral infection. In both models, N‑AC treatment significantly enhanced the abundance of lung‑infiltrating CD8+ T cells, supporting the translational relevance of cysteine supplementation for reversing redox‑driven immune dysfunction in the context of severe respiratory viral disease.
The authors conclude that cysteine supplementation, implemented here as N‑acetylcysteine, represents a viable therapeutic approach to reverse redox‑driven immune dysregulation in severe respiratory viral infection, with particular relevance for the high‑risk cancer population. The trial permitted concomitant anti‑COVID therapies and was conducted under institutional IRB approval. Sequencing datasets will be deposited on dbGaP at publication; other clinical and experimental data are available in the main text or supplementary materials or from the corresponding author on reasonable request.
Competing interests disclosed by authors were reported in the source material. Specific numerical outcome data, statistical analyses, dosing regimens, and detailed patient‑level results were not provided in the source abstract and therefore are not summarized here.